GSDMD and COVID-19: Pharmacological inhibition of GSDMD through treatment with the inhibitor disulfiram reduces NET release and organ damage in a mouse model of SARS-CoV-2 infection, suggesting that GSDMD-dependent NETosis plays a critical role in COVID-19 immunopathology (84).